Latest news with #Sequencing
Business Wire
2 days ago
- Business
- Business Wire
Sequencing.com Announces Strategic Partnership with PGxAI to Drive Affordable Healthcare Through Advanced Pharmacogenomics
PALO ALTO, Calif.--(BUSINESS WIRE)-- a biotech company offering the world's largest platform for whole genome sequencing and personalized health insights, announced a strategic partnership with PGxAI, a leader in AI-driven pharmacogenomics. This collaboration will transform the pharmacogenomics field by combining cutting-edge genomic insights with real-world healthcare applications, ultimately enhancing patient outcomes and reducing adverse drug reactions. Announces Strategic Partnership with PGxAI to Drive Affordable Healthcare Through Advanced Pharmacogenomics Share As part of this initiative, PGxAI will roll out a suite of pharmacogenomic reports on that provide personalized drug implications based on an individual's genomic data. They directly address a critical healthcare need — reducing adverse drug reaction incidences, a leading cause of unnecessary healthcare costs and patient harm. The reports cover over 730 drugs and 40 genes — offering up to five times the coverage of competitors. 'Adverse drug reactions account for over $150 billion in excess healthcare costs annually in the U.S., ' said Allan Gobbs, PGxAI Executive Chairman and Co-Founder. ' Studies indicate that pharmacogenomics can reduce these incidents by 30%, representing a significant opportunity to optimize healthcare costs and make treatments more affordable and effective.' Dr. Brandon Colby, Founder and CEO, added, 'The demand for pharmacogenomic testing is rapidly growing. PGxAI's scientific rigor and comprehensive data coverage provide unmatched value to our customers, further driving the precision health movement.' 'More than 99% of individuals carry clinically relevant drug-gene variations, ' said Dr. Mike Zack, PGxAI CEO and Co-Founder. 'Leveraging this information enables safer, more effective treatment regimens, making precision pharmacogenomics an immediate reality for modern healthcare.' PGxAI's reports seamlessly integrate with major reporting formats from clinically actionable consumer genetic testing services. These integrations allow users to effortlessly upload their genetic data, unlocking actionable insights linked to FDA guidelines and leading pharmacogenomics consortiums. These reports also represent new revenue opportunities for laboratories working with genomic data. Zack emphasized, 'Our reports are plug-and-play for genomic labs, offering new revenue streams while delivering measurable benefits for patients.' Learn more about this partnership at About Founded in 2017 by Dr. Brandon Colby and based in Los Angeles, (Sequencing) is a biotech company offering the world's largest platform for whole genome sequencing and personalized health insights. While most DNA tests obtain less than 0.1% of DNA data, Sequencing DNA test bundles allow users to obtain 100% of their DNA sequencing data, and the company offers the most private DNA sequencing test on the market. Led by US medical doctors, geneticists, bioinformatics experts, and software developers, Sequencing helps users make proactive decisions with their healthcare provider and genetic counselors around rare diseases, cancer risks, autoimmune disorders, cardiovascular health, and much more. Learn more at LinkedIn, Instagram, TikTok, X, and Facebook. About PGxAI Launched in 2023, Palo Alto‑based PGxAI stands at the forefront of pharmacogenomics, leveraging AI and real-world data to drive innovation in precision medicine. The platform employs proprietary algorithms to personalize drug selection, dosage, and interaction management. PGxAI is led by a team of scientists, AI experts and serial entrepreneurs, including CEO and сo-founder Dr. Mike Zack, MD, PhD, a UCSF pharmacogenomics expert, and executive chairman and сo-founder Allan Gobbs, a seasoned Life Sciences VC. The advisory board includes Dr. Russ Altman of Stanford University and executives from Thermo Fisher, GE Healthcare, and Tempus AI. Backed by New York-based ATEM Capital and in strategic partnership with InterSystems, PGxAI seeks to address the critical need for tailored, effective therapies in healthcare, and set new standards for precision medicine.
Associated Press
21-04-2025
- Health
- Associated Press
7 Major Markets Epidermolysis Bullosa Epidemiology Forecasts Report, 2020-2024 & 2034
DUBLIN--(BUSINESS WIRE)--Apr 21, 2025-- The " Epidermolysis Bullosa - Epidemiology Forecast - 2034 " report has been added to 's offering. The report delivers an in-depth understanding of Epidermolysis Bullosa, historical and forecasted epidemiology trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. The report provides historical as well as forecasted epidemiology segmented by total prevalent cases of Epidermolysis Bullosa, total diagnosed prevalent cases of Epidermolysis Bullosa, gender-specific cases of Epidermolysis Bullosa, age-specific cases of Epidermolysis Bullosa, and type-specific cases of Epidermolysis Bullosa in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2020 to 2034. Key Highlights Scope of the Report Epidermolysis Bullosa Report Insights Epidermolysis Bullosa Report Key Strengths Epidermolysis Bullosa Report Assessment Key Topics Covered: 1. Key Insights 2. Report Introduction 3. Executive Summary of Epidermolysis Bullosa (EB) 4. Epidemiology Forecast Methodology 5. Epidermolysis Bullosa Epidemiology Overview at a Glance 5.1. Patient Share (%) of Epidermolysis Bullosa in 2020 5.2. Patient Share (%) of Epidermolysis Bullosa in 2034 6. Epidermolysis Bullosa (EB): Disease Background and Overview 6.1. Introduction 6.2. Causes of Epidermolysis Bullosa 6.3. Signs and Symptoms of Epidermolysis Bullosa 6.4. Pathogenesis of Epidermolysis Bullosa 6.5. Pathophysiology of Itch in Epidermolysis Bullosa Skin 6.6. Classification of Epidermolysis Bullosa 6.7. Genetic Bases of Epidermolysis Bullosa 6.8. Diagnosis of Epidermolysis Bullosa 6.8.1. Types of Laboratory Referral 6.8.1.1. Neonate With Skin Fragility 6.8.1.2. Pediatric and Adult Patients With Skin Fragility 6.8.1.3. Carrier Testing 6.8.1.4. Prenatal Diagnosis 6.8.2. Further Testing 6.8.2.1. Skin Biopsy 6.8.2.2. Molecular Testing 6.8.2.3. Genetic Testing for Epidermolysis Bullosa 6.8.2.3.1. Next-generation Sequencing (NGS) Targeted Gene Panel and Whole-exome Sequencing in Epidermolysis Bullosa 6.8.2.3.2. Sanger Sequencing (SS) 7. Epidemiology and Patient Population of the 7MM 7.1. Key Findings 7.2. Assumption and Rationale 7.3. Total Prevalent Cases of Epidermolysis Bullosa in the 7MM 7.4. Diagnosed Prevalent Cases of Epidermolysis Bullosa in the 7MM 7.5. The United States 7.5.1. Total Prevalent Cases of Epidermolysis Bullosa in the United States 7.5.2. Diagnosed Prevalent Cases of Epidermolysis Bullosa in the United States 7.5.3. Gender-specific Cases of Epidermolysis Bullosa in the United States 7.5.4. Age-specific Cases of Epidermolysis Bullosa in the United States 7.5.5. Type-specific Cases of Epidermolysis Bullosa in the United States 7.6. EU4 and the UK 7.7. Japan 8. Patient Journey 9. Appendix For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. View source version on CONTACT: Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 KEYWORD: INDUSTRY KEYWORD: GENERAL HEALTH PHARMACEUTICAL HEALTH SOURCE: Research and Markets Copyright Business Wire 2025. PUB: 04/21/2025 04:37 AM/DISC: 04/21/2025 04:37 AM
